Ann: DRUG RESISTANCE IN LUNG CANCER PROGRAM, page-18

Ok. . . Then we need to stop a few traders from dropping 4 million off the market cap with a less than 20 trades. We have thousands of shareholders. . . Supportive patients. . . Supportive doctors. . .

Aug 2014

Chief Investigator at Duke, Dr Keyur Patel, said: "The criteria for this first-in-man trial are appropriately robust. We appreciate Benitec Biopharma's patience with this process, while we continue our work to recruit, screen and dose the patients on this TT-034 trial.

We will maintain our focus on ensuring the trial is completed in as timely a fashion as the process allows."

Dr Patel's comments were supported by Dr Barry Mangum, Director of Clinical Pharmacology at Duke, who noted: "We remain vigilant in the quest for success. This therapy, if proven successful, will be life changing to those patients who desperately require eradication of HCV. We at Duke remain committed to support Benitec's efforts to complete the first trial of this promising treatment."

Insults : stop insulting yourselves and the doctors who refer patients into the trial. Doctors refer patients into the trial . . . It is extra work for the doctors.